APR-246 is tested in several phase II clinical trials together with carboplatin combination chemotherapy in patients with serous ovarian cancer with mutated p53 (NCT02098343), a combination of APR-246 with azacytidine in p53 mutant myeloid neoplasms (NCT03072043) and a combination of APR-246 with 5-FU and cisplatin in esophageal cancer (NCT02999893) [179]. Here, TP53 is linked to myeloid neoplasm.